Low-grade NMIBC

Oncology·MeSH: Non-Muscle Invasive Bladder Neoplasms

8 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Phase 2(7)

Drug	Company
TYRA-200	Tyra Biosciences, Inc. (TYRA)
TYRA-300 0.125 mg/kg	Tyra Biosciences, Inc. (TYRA)
TYRA-300 0.25 mg/kg	Tyra Biosciences, Inc. (TYRA)
TYRA-300 0.375 mg/kg	Tyra Biosciences, Inc. (TYRA)
TYRA-300 0.50 mg/kg	Tyra Biosciences, Inc. (TYRA)
TYRA-300 Dose TBD	Tyra Biosciences, Inc. (TYRA)
TYRA-300 Dose TBD	IDEAYA Biosciences, Inc. (IDYA)

Phase 1(1)

Drug	Company
TYRA-300	Tyra Biosciences, Inc. (TYRA)

Compare drugs

TYRA-200 vs TYRA-300 0.125 mg/kg TYRA-200 vs TYRA-300 0.25 mg/kg TYRA-200 vs TYRA-300 0.375 mg/kg

Frequently asked questions

How many drugs are in development for Low-grade NMIBC?

BioSniper tracks 8 drugs in development for Low-grade NMIBC across 2 companies.

How many clinical trials target Low-grade NMIBC?

There are 1 clinical trial targeting Low-grade NMIBC tracked by BioSniper.

Deep-dive into Low-grade NMIBC

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Low-grade NMIBC — Drugs in Development & Clinical Trials | BioSniper